Artificial Intelligence in Advancing Inflammatory Bowel Disease Management: Setting New Standards
Cancers · 14.07.2025 · 17 (14) · 2337
DOI: 10.3390/cancers17142337 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 14.07.2025. Verfasst von Nunzia Labarile und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, National Institute of Gastroenterology-IRCCS "Saverio de Bellis"-Castellana Grotte, 70013 Bari, Italy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Artificial intelligence (AI) is increasingly being applied to improve the diagnosis and management of inflammatory bowel disease (IBD). Aims and Methods: We conducted a narrative review of the literature on AI applications in IBD endoscopy, focusing on diagnosis, disease activity assessment, therapy prediction, and detection of dysplasia.
Results
AI systems have demonstrated high accuracy in assessing endoscopic and histological disease activity in ulcerative colitis and Crohn’s disease, with performance comparable to expert clinicians. Machine learning models can predict response to biologics and risk of complications. AI-assisted technologies like confocal laser endomicroscopy enable real-time histological assessment. Computer-aided detection systems improve identification of dysplastic lesions during surveillance. Challenges remain, including need for larger datasets, external validation, and addressing potential biases.
Conclusions
AI has significant potential to enhance IBD care by providing rapid, objective assessments of disease activity, predicting outcomes, and assisting in dysplasia surveillance. However, further validation in diverse populations and prospective studies are needed before widespread clinical implementation. With ongoing advances, AI is poised to become a valuable tool to support clinical decision-making and improve patient outcomes in IBD. Addressing methodological, regulatory, and cost barriers will be crucial for the successful integration of AI into routine IBD management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, National Institute of Gastroenterology-IRCCS "Saverio de Bellis"-Castellana Grotte, 70013 Bari, Italy.
- Department of Medicine and Surgery, University of Enna 'Kore', 94100 Enna, Italy.
- Gastroenterology Unit, Umberto I Hospital, 94100 Enna, Italy.
- Gastroenterology Unit, Fondazione Istituto San Raffaele Giglio, 90015 Cefalù, Italy.
- Gastroenterology Unit, Department of Public Health, University of Naples Federico II, 80131 Naples, Italy.
- Gastroenterology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy.
ORCID-Profile: Nunzia Labarile, Alessandro Vitello, Olga Maria Nardone, Giulio Calabrese, Marcello Maida
Zitieren
APA
Labarile, N., Vitello, A., Sinagra, E., Nardone, O. M., Calabrese, G., Bonomo, F., Maida, M., & Iacucci, M. (2025). Artificial Intelligence in Advancing Inflammatory Bowel Disease Management: Setting New Standards. Cancers, 17(14), 2337. https://doi.org/10.3390/cancers17142337
Vancouver
Labarile N, Vitello A, Sinagra E, Nardone OM, Calabrese G, Bonomo F, et al. Artificial Intelligence in Advancing Inflammatory Bowel Disease Management: Setting New Standards. Cancers. 2025;17(14):2337. doi:10.3390/cancers17142337
BibTeX
@article{Labarile2025,
author = {Labarile, Nunzia and Vitello, Alessandro and Sinagra, Emanuele and Nardone, Olga Maria and Calabrese, Giulio and Bonomo, Federico and Maida, Marcello and Iacucci, Marietta},
title = {Artificial Intelligence in Advancing Inflammatory Bowel Disease Management: Setting New Standards},
journal = {Cancers},
year = {2025},
volume = {17},
number = {14},
pages = {2337},
doi = {10.3390/cancers17142337}
}
EUVIMED